Qipeng Yao
Shiyin Chen1†
Weiwei Qian
Chao Yang- 1Department of Chinese Medicine, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
- 2Emergency Department, Chengdu Shangjin Nanfu Hospital, Chengdu, Sichuan, China
- 3Department of Traditional Chinese Medicine Surgery, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
Colorectal cancer (CRC) is a highly prevalent and lethal malignancy worldwide, whose development is closely associated with gut microbiota dysbiosis and immune microenvironment imbalance. Interferons (IFNs) serve not only as pivotal cytokines bridging innate and adaptive immunity but also induce multiple forms of programmed cell death (PCD), playing a crucial role in antitumor immunity. This narrative review examines the core mechanisms of the gut microbiota-IFNs-programmed cell death axis within the CRC immune microenvironment. As upstream regulators, gut microbiota profoundly influence the production and function of type I, II, and III interferons through metabolic products and microbial-associated molecular patterns (MAMPs). Conversely, IFNs, serving as the pivotal link between innate and adaptive immunity, directly participate in tumor immune surveillance while also determining tumor cell fate by finely regulating PCD pathways such as apoptosis, autophagy, pyroptosis, and ferroptosis. In the CRC context, protective microbiota enhances IFN signaling and promote immunogenic PCD, activating effective antitumor immunity. Conversely, carcinogenic microbiota suppresses IFN responses, disrupt immune surveillance, and drive immune evasion and drug resistance. In-depth investigation of the mechanisms by which gut microbiota modulate interferon-mediated programmed cell death in CRC not only offers new insights into CRC immune evasion but also provides a theoretical foundation for developing combined immunotherapy strategies based on microbiota intervention, targeting IFN pathways, or regulating PCD patterns.
1 Introduction
Colorectal cancer (CRC) ranks as the third most prevalent and second deadliest malignant tumor globally. According to GLOBOCAN 2020 statistics, annual new cases and deaths amount to approximately 1.9 million and 900,000, respectively (1). With population aging and lifestyle changes, its incidence continues to rise in developing countries, posing a significant public health burden (2). The development of CRC exhibits high heterogeneity, involving multifactorial influences such as genetic mutations, environmental factors, immune dysregulation, metabolic disorders, and gut microbiota imbalance (1, 3–5). However, its precise pathogenesis remains incompletely elucidated. Notably, the gut microbiota—as a core microecosystem maintaining intestinal mucosal barriers, immune homeostasis, and metabolic equilibrium—has gained increasing prominence in CRC research (6–8). Research indicates that dysbiosis can promote polyp formation and tumor progression through mechanisms such as disrupting mucosal integrity, inducing metabolic abnormalities, and producing carcinogens (9–12). Furthermore, the gut microbiota composition of CRC patients exhibits significant differences compared to healthy individuals. Functional experiments and animal models have further confirmed that multiple bacteria play key roles in CRC development (13, 14). Conversely, probiotics can reduce CRC risk by regulating microbial balance and inhibiting pathogenic bacterial proliferation (15, 16). Therefore, elucidating the specific mechanisms of gut microbiota in CRC development and immune regulation is crucial for uncovering the disease’s etiology, developing novel biomarkers, and establishing microbiome-based intervention strategies.
Interferons (IFNs) serve as core cytokines in both innate and adaptive immunity, with functions spanning antiviral defense, tumor immune surveillance, and inflammatory response regulation (17–19). Based on structural and receptor differences, IFNs are primarily classified into Type I, Type II, and Type III. They activate signaling pathways such as JAK–STAT to induce expression of downstream interferon-stimulated genes (ISGs), thereby achieving broad immunomodulatory effects. Beyond their classic antiviral and antitumor roles, IFNs also participate in shaping the immune microenvironment and eliminating tumor cells by regulating multiple forms of programmed cell death (PCD), including apoptosis, autophagy, pyroptosis, and ferroptosis (20). Recent studies reveal a close regulatory relationship between the IFN signaling pathway and the gut microbiota: microbial composition and its metabolites significantly influence IFN production and function; conversely, IFNs can also affect microbial structure and the tumor immune microenvironment by inducing PCD and exerting immunomodulatory effects (21–23).
Exploring the interactions among gut microbiota, interferons, and programmed cell death, along with their regulatory mechanisms in the CRC immune microenvironment, holds significant scientific and clinical value. This paper aims to present a narrative review of the IFN signaling pathway and PCD mechanisms, elucidate the interactive relationship between gut microbiota and IFN, and focus on analyzing the action mechanisms of this regulatory axis within the CRC immune microenvironment. This endeavor seeks to provide new theoretical foundations and potential targets for immunotherapy strategies in colorectal cancer.
2 Regulatory role of gut microbiota in the immune microenvironment of CRC
The development of colorectal cancer is influenced not only by host genetic mutations and the infiltration status of immune cells, but also profoundly regulated by the homeostasis and dysbiosis of the gut microbiota. A growing body of research indicates that gut microbiota profoundly shapes the tumor immune microenvironment through metabolic products, signaling molecules, and interactions with immune cells. This bidirectional regulatory relationship between microbiota and the immune microenvironment not only reveals key mechanisms underlying CRC development.
2.1 Gut microbiota
The human microbiome constitutes a dynamic ecosystem comprising approximately 1014 microorganisms spanning around 3,000 species, including bacteria, fungi, and viruses. Significant variations exist in the quantity and abundance of different microbial types, with high heterogeneity in composition among individuals. Bacteria dominate quantitatively and exert profound effects on host health (24, 25). This ecosystem plays a crucial role in maintaining physiological homeostasis and functional balance. The vast majority of microorganisms colonize the gastrointestinal tract, with the highest density found in the colon, forming the extensively studied “gut microbiota” (26).
Among the diverse array of bacteria, the phyla Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria represent the major dominant groups (27, 28). Research indicates that the gut microbiota participates in regulating multiple physiological functions of the host: in digestion and nutrient metabolism, they assist in breaking down dietary components difficult for the host to digest (such as cellulose), produce short-chain fatty acids (SCFAs) through fermentation to provide energy for the host, and participate in vitamin synthesis and absorption (29, 30). Regarding immune regulation, gut microbiota is crucial for the maturation and development of the immune system (31, 32). Disruption of the host-microbiota balance leads to dysbiosis, manifested by reduced microbial diversity, imbalanced dominant species ratios, altered metabolic profiles, and abnormal secretion of vesicles and signaling molecules. Dysbiosis can impair intestinal mucosal barrier function, trigger chronic inflammatory responses, disrupt immune tolerance, and facilitate pathogenic bacterial colonization, thereby affecting host metabolic homeostasis. These alterations are closely associated with the development of diseases and physiological dysregulation, including inflammatory bowel disease, metabolic syndrome, neurological disorders, and various cancers (33, 34).
2.2 Colorectal cancer and gut microbiota
The immune microenvironment of colorectal cancer constitutes a highly dynamic ecosystem, where the types, density, and spatial distribution of immune cells exert decisive influence on tumor progression and patient prognosis. The quantity and localization of tumor-infiltrating lymphocytes (TILs), such as CD8+ T cells and CD45RO+ memory T cells, serve as critical survival predictors. The resulting “immunoscore” has emerged as an independent prognostic tool beyond TNM staging, driving the development of TNM-Immune integrated staging (35–37). Effector T cells, NK cells, and M1 macrophages suppress tumors through cytotoxic actions. The consensus molecular subtyping (CMS) of CRC further reveals its immune heterogeneity: CMS1 represents an immune-activated subtype sensitive to immunotherapy, while CMS4 is enriched with immunosuppressive cells and carries a poorer prognosis (3). Immune checkpoint inhibitors demonstrate significant efficacy in dMMR/MSI-H patients, highlighting the critical regulatory role of immune infiltration status in treatment response (38).
In recent years, research has increasingly revealed that the gut microbiota plays a crucial role in shaping the immune microenvironment of CRC (39). Under steady-state conditions, the gut microbiota maintains intestinal homeostasis by preserving the mucosal barrier, competitively inhibiting pathogenic bacteria, producing metabolites, and regulating mucosal immunity. However, reduced microbial diversity, enrichment of pro-carcinogenic strains, or depletion of beneficial bacteria disrupts this equilibrium, promoting precancerous lesions and tumorigenesis (8, 40). The microbiota of CRC patients often exhibits a pattern of “oncogenic bacteria enrichment—beneficial bacteria depletion”: significant increases in enterotoxigenic Bacteroides fragilis (ETBF), Fusobacterium nucleatum, and pks island-carrying Escherichia coli, alongside marked reductions in butyrate-producing bacteria (41, 42). Specifically, ETBF secretes BFT toxin, which disrupts the epithelial barrier, activates STAT3 and Wnt signaling, and promotes IL-17/IL-23 inflammatory axis activation, thereby accelerating tumorigenesis (43). F. nucleatum activates the β-catenin pathway via its adhesion protein FadA to upregulate oncogenes, and suppresses NK and T cell function by binding TIGIT through its Fap2 protein, thereby achieving immune evasion (44, 45). pks+ E. coli synthesizes colibactin, directly causing DNA damage and accumulating mutations (46–48). Furthermore, certain microbial metabolites like secondary bile acids (deoxycholic acid, DCA) induce DNA damage and accelerate carcinogenesis (49). Conversely, beneficial bacteria and their metabolites exert protective effects in CRC prevention and control. SCFAs particularly butyrate, serve as both an energy substrate for epithelial cells and a histone deacetylase inhibitor that promotes cancer cell apoptosis. They also enhance CD8+ T cell and memory T cell function, thereby improving antitumor immunity and mitigating the proinflammatory environment (50, 51). Probiotics such as Lactobacillus, Bifidobacterium, and Faecalibacterium prausnitzii have also been shown to reduce CRC risk by maintaining intestinal barrier integrity, secreting anti-inflammatory metabolites, and modulating immune responses (52, 53) (Table 1).
Table 1. Gut microbiota-induced colon cancer.
In the development of CRC, the interaction between the gut microbiota and the host immune system forms a complex regulatory network. Specific microbial communities can drive tumor progression by inducing immune suppression and chronic inflammation, while beneficial microbiota exert protective effects by activating anti-tumor immunity. The underlying mechanisms of this microbiota-immune interaction are closely linked to the regulation of core immune signaling pathways, such as those involving interferons.
3 Interferon signaling pathways and programmed cell death mechanisms
3.1 Fundamental biological functions of interferons
Interferons are a class of cytokines produced by host cells in response to stimuli such as viral infection, exhibiting antiviral, immunomodulatory, and antitumor functions. Based on differences in expression sources, target cell specificity, and immunoregulatory functions, they are primarily classified into Type I, Type II, and Type III. These interferons synergistically activate distinct signaling pathways and immune mechanisms, playing a pivotal regulatory role in bridging innate and adaptive immunity. They constitute a critical safeguard for the body against diverse pathogen infections and for maintaining immune homeostasis (19, 57, 58).
3.1.1 Type I interferons
Type I interferons (IFN-Is), first identified in 1957, have long been recognized as essential antiviral mediators of the innate immune response (59, 60). IFN-I family comprises 17 functional members in humans and 18 in mice and is produced primarily by dendritic cells, epithelial cells, and macrophages upon sensing pathogen-derived nucleic acids or damage-associated signals (19, 61, 62). The IFNAR receptor complex is broadly expressed on nucleated cells, enabling IFN-I to induce a wide array of interferon-stimulated genes (ISGs) through the JAK–STAT signaling pathway (17, 63), while negative regulators such as SOCS maintain signaling homeostasis and prevent immunopathology (64, 65). Functionally, IFN-I enhances NK cell cytotoxicity and promotes dendritic cell maturation, as well as T and B cell responses (66–69). However, persistent or excessive IFN-I signaling can induce PD-L1 upregulation, T-cell exhaustion, and chronic inflammation, thereby impairing antiviral or antitumor immunity (70–74). Therefore, precise regulation of IFN-I signaling is crucial for maintaining immune homeostasis and achieving antitumor therapeutic outcomes.
Recent studies have demonstrated that the gut microbiota enhances host IFN-I responses through multiple innate immune pathways. Microbiota-derived LPS, CpG-DNA, and flagellin can activate TLR4, TLR9, and TLR5, respectively, thereby inducing IFN-I production via IRF3/7 signaling (75–77). In addition, bacterial DNA or outer membrane vesicles (OMVs) can be internalized by host cells and trigger the cGAS–STING pathway, further amplifying IFN-I signaling (78). Moreover, short-chain fatty acid (SCFA)–producing Blautia species, as well as probiotic strains such as Lactobacillus rhamnosus GG, can promote IFN-I production through the MAVS–IRF3–IFNAR axis, thereby supporting basal antiviral immunity (79, 80).
3.1.2 Type II interferon
Type II interferon (IFN-γ) is the sole member of the type II interferon family and is primarily produced by activated NK cells and Th1/CD8+ T cells in response to antigenic or cytokine stimulation such as IL-12 and IL-18 (81, 82). Upon binding to its receptor IFNGR1/2, IFN-γ activates the JAK1/JAK2–STAT1 signaling axis, leading to γ-activated factor (GAF)–dependent transcription of interferon-responsive genes (83, 84). Functionally, IFN-γ enhances the antimicrobial activity of macrophages, upregulates MHC-I/II to improve antigen presentation, promotes Th1 and CTL-mediated cellular immunity, and suppresses Th2 and Treg responses (81–83, 85). Within the tumor microenvironment, IFN-γ facilitates immune cell infiltration and antigen visibility, contributing to tumor immunosurveillance and growth control (86, 87).
Gut microbiota exerts profound regulatory effects on the induction and effector functions of IFN-γ through multiple layers of immune modulation. First, microbe-associated molecular patterns such as LPS, CpG-DNA, and flagellin activate TLR4, TLR9, and TLR5 on dendritic cells and macrophages, inducing Th1-polarizing cytokines including IL-12 and IL-18 and thereby directly promoting IFN-γ production by NK cells and Th1/CD8+ T cells (88–91). Second, bacterial DNA or outer membrane vesicles (OMVs) entering host cells can activate the cGAS–STING pathway, enhancing antigen presentation and co-stimulatory molecule expression in dendritic cells, which raises the threshold for T-cell IFN-γ induction (92, 93). In addition, microbial metabolites critically shape IFN-γ programs: short-chain fatty acids (SCFAs) modulate IL-12 production by dendritic cells and promote CD8+ T-cell effector differentiation (94, 95), and indole derivatives regulate mucosal immune homeostasis through AHR signaling, thereby influencing IFN-γ expression in Th1 and NK cells (96, 97). Certain probiotics, including Bifidobacterium and Lactobacillus species, have also been shown to enhance Th1 polarization and NK-cell activation, further augmenting IFN-γ responses (98).
3.1.3 Type III interferons
Type III interferon (IFN-λ) encompass human IFN-λ1 through λ4, first reported by Sheppard and Kotenko et al. in 2003 (99, 100). Structurally similar to the IL-10 family, this group exhibits typical interferon functions. Their receptor complex comprises IFNLR1 (interferon lambda receptor 1) and IL-10Rβ (IL-10 receptor subunit beta), primarily expressed on epithelial cells and some neutrophils (19, 101). They demonstrate marked tissue specificity.
The signaling mechanism activated by IFN-λ resembles that of IFN-I, also promoting STAT1/2 phosphorylation through the JAK–STAT pathway and forming the ISGF3 complex to drive ISG expression (102). Unlike systemically acting IFN-I, IFN-III primarily induce a localized, mild, and persistent antiviral state in mucosal epithelium, avoiding systemic inflammation and immunopathology (103–105). Consequently, IFN-λ possesses unique advantages in maintaining barrier immune homeostasis, restricting viral mucosal replication, and protecting tissues from inflammatory damage, playing a critical role in mucosal defense, particularly in the respiratory, digestive, and reproductive tracts (106).
3.2 Interferon regulation of programmed cell death
Programmed cell death is a genetically regulated, proactive form of cell death executed according to specific protocols. Unlike passive necrosis, it plays a critical role in development, homeostasis maintenance, and immune responses. Based on molecular mechanisms and morphological characteristics, PCD primarily encompasses apoptosis, autophagy, pyroptosis, and ferroptosis. Interferons exert fine-tuned regulatory effects across multiple PCD pathways. By modulating interactions between death signals and immune effector cells, they shape the immune microenvironment and determine cellular fate.
3.2.1 Apoptosis
Apoptosis is a non-inflammatory, energy-dependent form of cell death that is crucial for development, immune homeostasis, and tumor defense. Characterized by cell shrinkage, membrane vesiculation, chromatin condensation, and the formation of apoptotic bodies, it maintains tissue homeostasis by eliminating abnormal or damaged cells. Imbalances in apoptosis are closely associated with tumors, neurodegenerative diseases, and autoimmune disorders (107, 108).
At the molecular level, apoptosis is mediated by the extrinsic death receptor pathway and the intrinsic mitochondrial pathway. The extrinsic pathway activates caspase-8 via Fas or TNFR; the intrinsic pathway induces mitochondrial release of cytochrome c and activates caspase-9 following stress or DNA damage, ultimately converging on effector caspase-3. The Bcl-2 family regulates this process: Bcl-2 and Bcl-xL inhibit apoptosis, while Bax, Bak, and Bid promote it (109–112). Anti-tumor strategies targeting apoptosis have garnered significant attention. Compounds such as the small molecule YLT322, red amine acid, resveratrol, and platycodin D can induce apoptosis via the mitochondrial pathway and enhance immune responses (113–116).
Interferons promote apoptosis by coupling exogenous and endogenous signals, playing a pivotal role in tumor immunity. IFNs upregulate death ligands such as TRAIL (tumor necrosis factor–related apoptosis-inducing ligand), FasL (Fas ligand), and TNF-α (Tumor necrosis factor alpha), activating the caspase-8 cascade; caspase-8 further cleaves Bid to generate tBid, enhancing mitochondrial membrane permeability and amplifying apoptotic signals (117–121). Concurrently, IFNs upregulate pro-apoptotic factors STAT1, IRF1, Bim, and XAF1 while suppressing Bcl-2 expression, heightening cellular sensitivity to apoptotic stimuli (117, 118, 122). Notably, IFN-γ induces iNOS expression and synergistically activates BAX/BAK with caspase-8, intensifying apoptotic effects in tumor cells (120).
3.2.2 Autophagy
Autophagy is an intracellular degradation pathway unique to eukaryotic cells. It maintains cellular homeostasis and energy balance by forming autophagosomes that engulf damaged organelles or proteins, which are then degraded upon fusion with lysosomes (123, 124). Autophagy plays crucial roles in responding to nutrient deprivation, oxidative stress, pathogen invasion, and antigen presentation (123, 125). Based on substrate delivery mechanisms, autophagy is categorized into macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA), which collaborate to sustain cell survival and stress adaptation (126).
Interferons induce autophagy and modulate immune responses through multiple signaling pathways. IFN-γ activates autophagy by upregulating autophagy genes such as Beclin1 and ATG5 via IRF1, promoting ROS accumulation, and activating the AMP-activated protein kinase (AMPK)–mechanistic target of rapamycin (mTOR) inhibitory axis. It also synergistically mediates tumor cell death with apoptosis (127, 128). IFN-I regulates Beclin1 and microtubule-associated protein 1 light chain 3 beta (LC3B) expression via the JAK–STAT pathway, inducing autophagy in a dose-dependent manner across multiple models including hepatocellular carcinoma (129), and can influence autophagy protein stability through miRNA-mediated post-transcriptional regulation (130). IFN-III similarly promote autophagy and lysosome formation in a dose-dependent manner in osteosarcoma cells, inhibiting cell invasion and metastasis (131). Furthermore, IFNs regulate autophagosome formation through the stimulator of interferon genes (STING)–TANK-binding kinase 1 (TBK1) pathway and ubiquitination of the autophagy receptor p62/SQSTM1 (132). Collectively, interferon-induced autophagy not only participates in cell death but also maintains metabolic and immune homeostasis in antiviral defense and antitumor immunity.
3.2.3 Pyroptosis
Pyroptosis is a form of inflammasome-dependent programmed cell death characterized by distinct proinflammatory features (133). Its hallmarks include cellular swelling, membrane rupture, leakage of cellular contents, and release of IL-1β and IL-18. Pyroptosis serves an immune defense function by eliminating infected cells and activating inflammation, but uncontrolled pyroptosis can cause tissue damage. The canonical pathway involves pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) activating receptors such as NLRP3, NLRC4, or AIM2, leading to inflammasome assembly and caspase-1 activation, which cleaves gasdermin D (GSDMD) and releases cytokines. In the non-canonical pathway, caspase-4/5 (human) or caspase-11 (mouse) directly recognizes intracellular lipopolysaccharide (LPS), cleaves GSDMD to form membrane pores, and further activates NLRP3 to amplify the response (133–137).
Interferons regulate pyroptosis through multiple mechanisms. IFN-I induce the expression of ZBP1 (Z-DNA-binding protein 1), MLKL (mixed lineage kinase domain-like protein), caspase-11, and GSDMD, thereby promoting NLRP3 activation and GSDMD-dependent pyroptosis (138). In severe acute pancreatitis, mitochondrial DNA activates NLRP3 via the cGAS–STING (cyclic GMP–AMP synthase–stimulator of interferon genes) pathway, exacerbating macrophage pyroptosis and inflammatory responses (139). IFN-III exert negative regulation by upregulating ZBP1 and activating the caspase-8/GSDMC pathway to induce intestinal epithelial pyroptosis, thereby delaying epithelial repair after colitis or radiation injury. This pathway is highly activated in inflammatory bowel disease (119). In tumor immunity, interferons can induce pyroptosis mediated by caspase-1 or caspase-4/5/11 through NLRP3 or cGAS–STING pathways, releasing IL-1β and IL-18 to promote immune cell infiltration and antitumor responses. Studies demonstrate that IFN-γ induces caspase-4 expression in lung adenocarcinoma cells, triggering pyroptosis under high-concentration stimulation. Inhibiting the negative regulator USP18 (ubiquitin-specific peptidase 18) enhances STAT2 activity and induces immunogenic pyroptosis, thereby amplifying antitumor effects (140, 141). Furthermore, in renal cell carcinoma, STING deletion or degradation via the PROTAC agent SP23 activates GSDMD-dependent pyroptosis through the PERK/eIF2α/ATF4/CHOP–caspase-8 axis, enhancing CD4+/CD8+ T cell infiltration and thereby strengthening antitumor immunity (142). These findings indicate that interferon regulates immunogenic cell death via the pyroptotic pathway in both anti-infection and tumor immunity.
3.2.4 Ferroptosis
Ferroptosis is an iron-dependent, lipid peroxidation-driven form of cell death distinct from apoptosis and necrosis. Its hallmark features include excessive intracellular free iron accumulation, markedly elevated reactive ROS levels, massive accumulation of membrane lipid peroxides, and dysfunction of the glutathione peroxidase 4 (GPX4) antioxidant defense system (143–145). Its core mechanism involves glutathione (GSH) depletion and loss of GPX4 activity, leading to the oxidation of polyunsaturated fatty acids (PUFAs) into phospholipid peroxides (PL-OOH) (146). Intracellular Fe²+ generates reactive oxygen species (·OH) via the Fenton reaction, further amplifying lipid peroxidation (147). When System Xc− transporter function is inhibited, reduced cystein uptake limits GSH synthesis, preventing GPX4 from reducing PL-OOH and ultimately triggering ferroptosis (148). Although cells can provide alternative antioxidant mechanisms via the FSP1–CoQ10 and GCH1–BH4 pathways, these remain insufficient to prevent lipid membrane damage under high oxidative stress (149, 150). Iron metabolism-related proteins (TFR1, FTH1, FPN) and transcription factors p53 and NRF2 also participate in iron homeostasis regulation (151, 152).
Interferon plays a pivotal role in regulating ferroptosis. IFN-γ downregulates the expression of System Xc− subunits SLC3A2 (solute carrier family 3 member 2) and SLC7A11 (solute carrier family 7 member 11) via the JAK/STAT1 pathway, inhibiting cystine uptake. This leads to glutathione (GSH) depletion, GPX4 inactivation, and lipid peroxidation accumulation, thereby inducing ferroptosis in tumor cells (153). This mechanism significantly enhances tumor sensitivity to immunotherapy and correlates closely with anti-PD-1 efficacy (154). Ferroptosis also releases DAMPs, activating dendritic cells and promoting cross-presentation of antigens, thereby enhancing CTL and NK cell function (155). Furthermore, ferroptosis-derived lipid peroxidation products can induce IFN-I responses via the cGAS–STING pathway, promoting dendritic cell maturation and T cell expansion, thereby amplifying antitumor immune effects (156). Preclinical studies demonstrate that ferroptosis inducers combined with immune checkpoint inhibitors significantly enhance immune responses and tumor suppression, providing a novel theoretical basis for combined immunotherapy and metabolic targeting strategies (157, 158).
4 Gut microbiota modulates interferon-induced programmed cell death in colorectal cancer
The gut microbiota, interferon, and programmed cell death collectively form a core network sustaining intestinal immune homeostasis. Under healthy conditions, this axis achieves a balance between host defense and tissue repair by the microbiota positively regulating interferon production, while interferon induces moderate PCD to maintain barrier renewal and microbial diversity (21). However, during colorectal cancer development, this network progressively dysregulates, transforming from a protective mechanism into a key driver of immune evasion and tumor progression (17). Microbiota modulate interferon signaling. The commensal microbiota activates interferon expression from diverse sources through molecular patterns and metabolic products. Macrophages and plasmacytoid dendritic cells (pDCs) secrete IFN-I in response to microbial stimulation, while intestinal epithelial cells IFN-λ. These signals are essential for initiating and sustaining natural killer (NK) cell and CD8+ T cell function. Furthermore, pDC-derived IFN-I enhances antigen presentation capacity in conventional dendritic cells (cDCs) through epigenetic reprogramming (21, 159).
4.1 Gut microbiota modulates type I interferon-induced apoptosis in colorectal cancer
In colorectal cancer, IFN-I bridge innate immune recognition with tumor cell apoptosis. Cytoplasmic DNA fragments induced by radiotherapy or chemotherapy can trigger IFN-I expression via the cGAS–STING pathway. Microbiota-associated molecules, such as bacterial DNA and cyclic dinucleotide c-di-AMP, can also enhance this signaling through the same pathway, and microbiota-derived molecules can amplify IFN-I signaling via this pathway. Poly-γ-glutamic acid from Bacillus species, Bacteroides fragilis polysaccharide A (PSA), and Lactobacillus nucleic acids can all induce IFN production via TLR4, RIG-I-like receptors (RLRs), or the cGAS pathway (78, 160–163). Metabolites are equally important: SCFAs produced by the family Clostridiaceae enhance IFN-I expression via GPR43 (164); secondary bile acids converted by Clostridium species induce pDCs to secrete IFN-I (165).
At the level of tumor immune surveillance, IFN-I induce programmed tumor cell apoptosis by upregulating TRAIL and its receptors and activating caspase-8 (166, 167); promoting mitochondrial depolarization, decreasing Bcl-xL while increasing Bim and PARP-associated signals with AIF translocation (168), and enhancing DC maturation, antigen cross-presentation, and CD8+ T-cell expansion (169). IFN-I further upregulates tumor-cell MHC-I expression (170, 171). It suppresses anti-apoptotic proteins Bcl-2 and Bcl-XL (172, 173) through Jak/STAT signaling, while synergizing with TRAIL via ERK signaling to promote apoptosis (Figure 1) (174). Except for apoptosis, IFN-I intersects with additional programmed cell death pathways in colorectal cancer. In ferroptosis, cGAS–STING–induced IFN-β increases intracellular Fe²+ and lipid peroxidation, lowers glutathione, and upregulates TRIM22, thereby amplifying RSL3-induced ferroptosis in HCT116 and other tumor cells (175, 176). In pyroptosis, IFN-I–induced guanylate-binding proteins (GBPs) facilitate caspase-11-dependent noncanonical inflammasome activation and GSDMD-mediated lytic death, and IFN-I signaling is required for full activation of the NLRP3 inflammasome (138, 177). Collectively, these findings indicate that gut microbiota–modulated IFN-I signaling integrates innate immune sensing with multiple programmed cell death modalities—including apoptosis, ferroptosis, and pyroptosis—to shape antitumor immunity in colorectal cancer.
Figure 1. Gut microbiota promotes interferon-induced tumor apoptosis. Gut microbiota–derived microbial signals activate pattern-recognition receptors, including TLRs, RLRs, and the cGAS–STING pathway, in intestinal epithelial cells, dendritic cells (DCs), and macrophages. Engagement of these innate immune sensors drives robust production of IFN-I. IFN-I upregulates death ligands (FasL, TRAIL) and enhances their engagement with death receptors on tumor cells, triggering FADD-mediated activation of caspases-8/10 and downstream effector caspases-3/6/7. Caspase-8–generated tBid activates Bax/Bak, inducing mitochondrial permeabilization and the release of cytochrome c and AIF. Cytochrome c promotes apoptosome formation and caspase-9 activation, whereas AIF facilitates chromatin condensation. Anti-apoptotic Bcl-2/Bcl-xL counteract this process. Together, extrinsic and intrinsic pathways converge to promote IFN-I–dependent tumor cell apoptosis.
4.2 Gut microbiota modulates type II interferon-induced programmed cell death in colorectal cancer
In the colorectal cancer microenvironment, tumor-infiltrating effector T cells and natural killer cells are the primary sources of IFN-γ, with secondary sources including Foxp3+ CD4+ regulatory T cells (Tregs), Th17 cells, Th22 cells, NKT cells, innate lymphoid cells (ILCs), and certain antigen-presenting cells (178). Microbiome homeostasis significantly impacts IFN-γ function: for instance, enrichment of Akkermansia muciniphila enhances IFN-γ+ CD8+ T cell infiltration and markedly improves PD-1 blockade efficacy; colon IFN-γ production increases substantially upon Gram-negative bacterial exposure, a process dependent on monocytes and myeloid dendritic cells (179). Furthermore, microbial metabolites such as SCFAs improve metabolic adaptability in CD8+ T cells and enhance their IFN-γ secretion capacity, thereby promoting ferroptosis and pyroptosis (180). They also influence IFN-γ production by regulating macrophage polarization (181). Conversely, dysbiosis or pathogenic bacteria (e.g., pks-carrying E. coli) weaken the IFN-γ–PD-1 pathway by releasing immunosuppressive factors, leading to immune tolerance and drug resistance (182, 183).
IFN-γ exerts multifaceted roles in antitumor immunity. It upregulates MHC-I/II expression in tumor cells and APCs, enhances antigen presentation, and promotes APC secretion of IL-12, thereby driving Th1 polarization. Concurrently, IFN-γ induces Th1-type chemokine production, facilitating tumor infiltration by T cells and NK cells. Additionally, IFN-γ directly inhibits tumor cell proliferation (184–186) and induces cancer cell apoptosis (180, 187, 188) and necrotic cell death (189) via mitochondrial pathways. Recent studies further reveal that IFN-γ drives ferroptosis by inhibiting System Xc−, reducing glutathione synthesis, and weakening GPX4 antioxidant defense—a mechanism critical for immune checkpoint inhibitor (ICI) efficacy (190). Ferroptosis serves as a critical determinant of tumor progression and clinical prognosis in colorectal cancer, with its associated gene expression closely correlated with patient survival—even outperforming traditional TNM staging in prognostic assessment (191, 192). Recent studies indicate that ferroptosis sensitivity is regulated by metabolic reprogramming and the mTORC1 signaling pathway. The combination of aspirin and RSL3 effectively induces ferroptosis in PIK3CA-mutant CRC cells by inhibiting the mTOR/SREBP-1/SCD1 axis (193). In-depth elucidation of its molecular mechanisms, particularly the identification of key ferroptosis-associated biomarkers, will provide novel insights and strategies for early diagnosis and personalized treatment of colorectal cancer. (Figure 2)
Figure 2. Molecular mechanism by which IFN-γ promotes ferroptosis in tumor cells. Gut microbiota–derived signals activate host immune pathways and promote CD8+ T-cell secretion of IFN-γ. IFN-γ engages the IFNGR1/IFNGR2 complex on tumor cells, triggering JAK1/2-mediated phosphorylation and activation of STAT1. Nuclear STAT1 induces IRF1, which transcriptionally represses the System Xc− components SLC7A11 and SLC3A2, thereby reducing cystine import and limiting GSH synthesis. GSH depletion decreases GPX4 activity, allowing lipid peroxides to accumulate. The resulting lipid peroxidation compromises membrane integrity and drives ferroptotic tumor cell death.
4.3 Gut microbiota modulates type III interferon-induced apoptosis in colorectal cancer
In colorectal cancer, IFN-III primarily act on intestinal epithelial cells, serving as “guardians” maintaining mucosal barrier homeostasis. Their main sources include intestinal epithelial cells themselves, mucosa-associated dendritic cells, and neutrophils under specific infectious conditions (194). Gut symbiotic microbiota (e.g., Enterobacteriaceae) can weaken mucosal defense by downregulating the IFN-III response, thereby promoting carcinogenic inflammatory environments. Conversely, antibiotic or probiotic interventions can partially restore IFN-λ signaling and improve immune homeostasis (195). Secondary bile acids converted by Clostridium species stimulate epithelial cells to secrete IFN-λ (196).
Under intestinal homeostasis, commensal microbiota induce localized IFN-λ–ISG responses in the small and large intestinal epithelium, whereas such tonic signaling is markedly diminished in germ-free or antibiotic-treated animals and can be restored upon microbial re-colonization, indicating that the microbiota are essential for maintaining baseline epithelial IFN-λ activation (197). In the tumor context, IFN-λ activates IFNLR1-dependent caspase-3/8/9 signaling to induce G1/G0 cell-cycle arrest and apoptosis in colorectal cancer cells, exhibiting stronger cytotoxicity than IFN-I or IFN-II (198), consistent in vitro and in vivo evidence that recombinant IFN-λ1 suppresses tumor growth in a dose-dependent manner (199). Moreover, IFN-λ upregulates ZBP1 and promotes caspase-8–mediated GSDMC cleavage, thereby inducing pyroptosis-like lytic cell death in intestinal epithelial cells (119). Although there is a lack of direct evidence that IFN-λ triggers ferroptosis or necroptosis-like cell death in CRC cells, its signaling intersects extensively with oxidative stress, inflammatory, and metabolic pathways, and its regulation of inflammasome- and cytokine-related genes suggests potential interactions with additional regulated cell death (RCD) programs (197, 200, 201). Given its role in restraining NLRP6/NLRP9b inflammasome activation and epithelial IFN-λ secretion, and its emerging involvement in PERK-dependent ER stress–induced apoptosis,TRIM29 dysregulation may constitute a critical molecular hub linking impaired mucosal immune homeostasis, increased susceptibility to enteric viral infection, attenuation of IFN-λ–dependent tumor-suppressive signaling, and inflammation-driven colorectal carcinogenesis (202–205).
5 Summary and outlook
This review provides a comprehensive overview of the multifaceted interactions and mechanisms among the gut microbiota, IFN signaling pathways, and PCD within the immune microenvironment of CRC. IFNs serve not only as a pivotal bridge linking innate and adaptive immunity but also influence tumor cell survival and immune response states by finely regulating multiple PCD modes, including apoptosis, autophagy, pyroptosis, and ferroptosis. As key upstream regulators, gut microbiota modulate IFN function through metabolites (e.g., short-chain fatty acids), microbial-associated molecular patterns (e.g., LPS), and immune signaling molecules. In CRC, “protective microbiota” enhances IFN signaling and promote immunogenic cell death, activating the DC–CD8+ T cell axis; conversely, “oncogenic microbiota” suppresses IFN responses, disrupt epithelial barriers, and recruit immunosuppressive cells, facilitating immune evasion and drug resistance.
Several critical questions remain in this field. The highly context-dependent and cell-type-specific nature of the microbiota–IFN–PCD axis, along with its role in different CRC molecular subtypes, spatial heterogeneity, and dynamic evolution, remains unclear. Techniques such as single-cell multi-omics and spatial transcriptomics hold promise for revealing cellular interaction networks at higher resolution (206, 207). Most mechanistic evidence remains derived from preclinical models, requiring large-scale clinical validation for human applicability and individual variability. Furthermore, the dual role of type III IFN in mucosal immunity and epithelial repair necessitates more precise regulatory strategies.
Intervention strategies may offer novel avenues for CRC immunotherapy. Dietary modulation, probiotic supplementation, or fecal microbiota transplantation (FMT) can reshape “immune-supportive” microbiota to enhance IFN signaling and anti-tumor PCD (208, 209). Multimodal therapies targeting IFN pathways (e.g., IFN-γ combined with immune checkpoint blockade) or downstream PCD effector molecules (e.g., ferroptosis inducers) may overcome treatment bottlenecks in pMMR/MSS-type CRC (207, 210, 211). An individualized immune scoring system integrating multi-omics data will advance precision classification and treatment of CRC (206), positioning the “microbiota–IFN–PCD” axis as a novel target for clinical translation and drug development.
Author contributions
QY: Conceptualization, Methodology, Writing – original draft. SC: Writing – original draft, Software, Project administration, Methodology. WQ: Methodology, Writing – original draft, Project administration. CY: Investigation, Writing – original draft, Methodology. JL: Writing – original draft, Methodology, Project administration, Validation.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2021) 71:209–49. doi: 10.3322/caac.21660, PMID: 33538338
2. Xie Y, Shi L, He X, and Luo Y. Gastrointestinal cancers in China, the USA, and europe. Gastroenterol Rep (Oxf). (2021) 9:91–104. doi: 10.1093/gastro/goab010, PMID: 34026216
3. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. (2015) 21:1350–6. doi: 10.1038/nm.3967, PMID: 26457759
4. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, and Wallace MB. Colorectal cancer. Lancet. (2019) 394:1467–80. doi: 10.1016/s0140-6736(19)32319-0, PMID: 31631858
5. Keum N and Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. (2019) 16:713–32. doi: 10.1038/s41575-019-0189-8, PMID: 31455888
6. Garrett WS. Cancer and the microbiota. Science. (2015) 348:80–6. doi: 10.1126/science.aaa4972, PMID: 25838377
7. Tilg H, Adolph TE, Gerner RR, and Moschen AR. The intestinal microbiota in colorectal cancer. Cancer Cell. (2018) 33:954–64. doi: 10.1016/j.ccell.2018.03.004, PMID: 29657127
8. Wong SH and Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol. (2019) 16:690–704. doi: 10.1038/s41575-019-0209-8, PMID: 31554963
9. Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan TJ, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. (2012) 338:120–3. doi: 10.1126/science.1224820, PMID: 22903521
10. Gagliani N, Hu B, Huber S, Elinav E, and Flavell RA. The fire within: microbes inflame tumors. Cell. (2014) 157:776–83. doi: 10.1016/j.cell.2014.03.006, PMID: 24813605
11. Iadsee N, Chuaypen N, Techawiwattanaboon T, Jinato T, Patcharatrakul T, Malakorn S, et al. Identification of a novel gut microbiota signature associated with colorectal cancer in Thai population. Sci Rep. (2023) 13:6702. doi: 10.1038/s41598-023-33794-9, PMID: 37095272
12. Pandey H, Tang DWT, Wong SH, and Lal D. Gut microbiota in colorectal cancer: biological role and therapeutic opportunities. Cancers (Basel). (2023) 15:866. doi: 10.3390/cancers15030866, PMID: 36765824
13. Janney A, Powrie F, and Mann EH. Host-microbiota maladaptation in colorectal cancer. Nature. (2020) 585:509–17. doi: 10.1038/s41586-020-2729-3, PMID: 32968260
14. Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. Isme J. (2012) 6:320–9. doi: 10.1038/ismej.2011.109, PMID: 21850056
15. Liang JQ, Zeng Y, Lau EYT, Sun Y, Huang Y, Zhou T, et al. A probiotic formula for modulation of colorectal cancer risk via reducing CRC-associated bacteria. Cells. (2023) 12:1244. doi: 10.3390/cells12091244, PMID: 37174650
16. Gao Z, Guo B, Gao R, Zhu Q, Wu W, and Qin H. Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer. Mol Med Rep. (2015) 12:6119–27. doi: 10.3892/mmr.2015.4124, PMID: 26238090
17. Ivashkiv LB and Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. (2014) 14:36–49. doi: 10.1038/nri3581, PMID: 24362405
18. Zaidi MR and Merlino G. The two faces of interferon-γ in cancer. Clin Cancer Res. (2011) 17:6118–24. doi: 10.1158/1078-0432.Ccr-11-0482, PMID: 21705455
19. Lazear HM, Schoggins JW, and Diamond MS. Shared and distinct functions of type I and type III interferons. Immunity. (2019) 50:907–23. doi: 10.1016/j.immuni.2019.03.025, PMID: 30995506
20. Abdulamir AS, Hafidh RR, and Abu Bakar F. The association of streptococcus bovis/gallolyticus with colorectal tumors: the nature and the underlying mechanisms of its etiological role. J Exp Clin Cancer Res. (2011) 30:11. doi: 10.1186/1756-9966-30-11, PMID: 21247505
21. Abt MC, Osborne LC, Monticelli LA, Doering TA, Alenghat T, Sonnenberg GF, et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity. (2012) 37:158–70. doi: 10.1016/j.immuni.2012.04.011, PMID: 22705104
22. Kotredes KP, Thomas B, and Gamero AM. The protective role of type I interferons in the gastrointestinal tract. Front Immunol. (2017) 8:410. doi: 10.3389/fimmu.2017.00410, PMID: 28428788
23. Yu AI, Zhao L, Eaton KA, Ho S, Chen J, Poe S, et al. Gut microbiota modulate CD8 T cell responses to influence colitis-associated tumorigenesis. Cell Rep. (2020) 31:107471. doi: 10.1016/j.celrep.2020.03.035, PMID: 32268087
24. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol. (1977) 31:107–33. doi: 10.1146/annurev.mi.31.100177.000543, PMID: 334036
25. Sender R, Fuchs S, and Milo R. Revised estimates for the number of human and bacteria cells in the body. PloS Biol. (2016) 14:e1002533. doi: 10.1371/journal.pbio.1002533, PMID: 27541692
26. Sender R, Fuchs S, and Milo R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell. (2016) 164:337–40. doi: 10.1016/j.cell.2016.01.013, PMID: 26824647
27. Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. (2019) 7:14. doi: 10.3390/microorganisms7010014, PMID: 30634578
28. Hou K, Wu Z-X, Chen X-Y, Wang J-Q, Zhang D, Xiao C, et al. Microbiota in health and diseases. Signal Transduction Targeted Ther. (2022) 7:135. doi: 10.1038/s41392-022-00974-4, PMID: 35461318
29. Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr. (2018) 57:1–24. doi: 10.1007/s00394-017-1445-8, PMID: 28393285
30. Grant ET, Parrish A, Boudaud M, Hunewald O, Hirayama A, Ollert M, et al. Dietary fibers boost gut microbiota-produced B vitamin pool and alter host immune landscape. Microbiome. (2024) 12:179. doi: 10.1186/s40168-024-01898-7, PMID: 39307855
31. McNeil NI. The contribution of the large intestine to energy supplies in man. Am J Clin Nutr. (1984) 39:338–42. doi: 10.1093/ajcn/39.2.338, PMID: 6320630
32. Gensollen T, Iyer SS, Kasper DL, and Blumberg RS. How colonization by microbiota in early life shapes the immune system. Science. (2016) 352:539–44. doi: 10.1126/science.aad9378, PMID: 27126036
33. Kovatcheva-Datchary P, Nilsson A, Akrami R, Lee YS, De Vadder F, Arora T, et al. Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of prevotella. Cell Metab. (2015) 22:971–82. doi: 10.1016/j.cmet.2015.10.001, PMID: 26552345
34. Viennois E, Gewirtz AT, and Chassaing B. Connecting the dots: dietary fat, microbiota dysbiosis, altered metabolome, and colon cancer. Gastroenterology. (2022) 162:38–9. doi: 10.1053/j.gastro.2021.10.018, PMID: 34687737
35. Fridman WH, Pagès F, Sautès-Fridman C, and Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. (2012) 12:298–306. doi: 10.1038/nrc3245, PMID: 22419253
36. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. (2006) 313:1960–4. doi: 10.1126/science.1129139, PMID: 17008531
37. Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, et al. International validation of the consensus immunoscore for the classification of colon cancer: A prognostic and accuracy study. Lancet. (2018) 391:2128–39. doi: 10.1016/s0140-6736(18)30789-x, PMID: 29754777
38. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. (2015) 372:2509–20. doi: 10.1056/NEJMoa1500596, PMID: 26028255
39. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-pd-1 immunotherapy in melanoma patients. Science. (2018) 359:97–103. doi: 10.1126/science.aan4236, PMID: 29097493
40. Garrett WS. The gut microbiota and colon cancer. Science. (2019) 364:1133–5. doi: 10.1126/science.aaw2367, PMID: 31221845
41. Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol. (2014) 10:766. doi: 10.15252/msb.20145645, PMID: 25432777
42. Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. (2012) 22:299–306. doi: 10.1101/gr.126516.111, PMID: 22009989
43. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. (2009) 15:1016–22. doi: 10.1038/nm.2015, PMID: 19701202
44. Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, and Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its fada adhesin. Cell Host Microbe. (2013) 14:195–206. doi: 10.1016/j.chom.2013.07.012, PMID: 23954158
45. Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, et al. Binding of the fap2 protein of fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. (2015) 42:344–55. doi: 10.1016/j.immuni.2015.01.010, PMID: 25680274
46. Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, van Hoeck A, Wood HM, Nomburg J, et al. Mutational signature in colorectal cancer caused by genotoxic pks+ E. Coli. Nat. (2020) 580:269–73. doi: 10.1038/s41586-020-2080-8, PMID: 32106218
47. Chen B, Ramazzotti D, Heide T, Spiteri I, Fernandez-Mateos J, James C, et al. Contribution of pks+ E. Coli mutations to colorectal carcinogenesis. Nat Commun. (2023) 14:7827. doi: 10.1038/s41467-023-43329-5, PMID: 38030613
48. Iftekhar A, Berger H, Bouznad N, Heuberger J, Boccellato F, Dobrindt U, et al. Genomic aberrations after short-term exposure to colibactin-producing E. Coli transform primary colon epithelial cells. Nat Commun. (2021) 12:1003. doi: 10.1038/s41467-021-21162-y, PMID: 33579932
49. Ridlon JM, Harris SC, Bhowmik S, Kang DJ, and Hylemon PB. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes. (2016) 7:22–39. doi: 10.1080/19490976.2015.1127483, PMID: 26939849
50. Louis P, Hold GL, and Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. (2014) 12:661–72. doi: 10.1038/nrmicro3344, PMID: 25198138
51. Donohoe DR, Holley D, Collins LB, Montgomery SA, Whitmore AC, Hillhouse A, et al. A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner. Cancer Discov. (2014) 4:1387–97. doi: 10.1158/2159-8290.Cd-14-0501, PMID: 25266735
52. Hibberd AA, Lyra A, Ouwehand AC, Rolny P, Lindegren H, Cedgård L, et al. Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention. BMJ Open Gastroenterol. (2017) 4:e000145. doi: 10.1136/bmjgast-2017-000145, PMID: 28944067
53. Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, et al. A decrease of the butyrate-producing species roseburia hominis and faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. (2014) 63:1275–83. doi: 10.1136/gutjnl-2013-304833, PMID: 24021287
54. Wang X and Huycke MM. Extracellular superoxide production by enterococcus faecalis promotes chromosomal instability in mammalian cells. Gastroenterology. (2007) 132:551–61. doi: 10.1053/j.gastro.2006.11.040, PMID: 17258726
55. Wang X, Allen TD, May RJ, Lightfoot S, Houchen CW, and Huycke MM. Enterococcus faecalis induces aneuploidy and tetraploidy in colonic epithelial cells through a bystander effect. Cancer Res. (2008) 68:9909–17. doi: 10.1158/0008-5472.Can-08-1551, PMID: 19047172
56. Long X, Wong CC, Tong L, Chu ESH, Ho Szeto C, Go MYY, et al. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. Nat Microbiol. (2019) 4:2319–30. doi: 10.1038/s41564-019-0541-3, PMID: 31501538
57. Pestka S, Krause CD, and Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. (2004) 202:8–32. doi: 10.1111/j.0105-2896.2004.00204.x, PMID: 15546383
58. McNab F, Mayer-Barber K, Sher A, Wack A, and O'Garra A. Type I interferons in infectious disease. Nat Rev Immunol. (2015) 15:87–103. doi: 10.1038/nri3787, PMID: 25614319
59. Isaacs A and Lindenmann J. Virus interference. I. The Interferon. Proc R Soc Lond B Biol Sci. (1957) 147:258–67. doi: 10.1098/rspb.1957.0048, PMID: 13465720
60. Borden EC. Interferons α and β in cancer: therapeutic opportunities from new insights. Nat Rev Drug Discov. (2019) 18:219–34. doi: 10.1038/s41573-018-0011-2, PMID: 30679806
61. Capobianchi MR, Uleri E, Caglioti C, and Dolei A. Type I IFN family members: similarity, differences and interaction. Cytokine Growth Factor Rev. (2015) 26:103–11. doi: 10.1016/j.cytogfr.2014.10.011, PMID: 25466633
62. Swiecki M and Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol. (2015) 15:471–85. doi: 10.1038/nri3865, PMID: 26160613
63. Platanias LC. Mechanisms of type-I- and type-ii-interferon-mediated signalling. Nat Rev Immunol. (2005) 5:375–86. doi: 10.1038/nri1604, PMID: 15864272
64. Malakhova OA, Kim KI, Luo JK, Zou W, Kumar KG, Fuchs SY, et al. Ubp43 is a novel regulator of interferon signaling independent of its isg15 isopeptidase activity. EMBO J. (2006) 25:2358–67. doi: 10.1038/sj.emboj.7601149, PMID: 16710296
65. Honda K, Mizutani T, and Taniguchi T. Negative regulation of IFN-α/β Signaling by IFN regulatory factor 2 for homeostatic development of dendritic cells. Proc Natl Acad Sci. (2004) 101:2416–21. doi: 10.1073/pnas.0307336101, PMID: 14983024
66. Madera S, Rapp M, Firth MA, Beilke JN, Lanier LL, and Sun JC. Type I Ifn Promotes Nk Cell Expansion during Viral Infection by Protecting Nk Cells against Fratricide. J Exp Med. (2016) 213:225–33. doi: 10.1084/jem.20150712, PMID: 26755706
67. Colonna M, Trinchieri G, and Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol. (2004) 5:1219–26. doi: 10.1038/ni1141, PMID: 15549123
68. Crouse J, Kalinke U, and Oxenius A. Regulation of antiviral T cell responses by type I interferons. Nat Rev Immunol. (2015) 15:231–42. doi: 10.1038/nri3806, PMID: 25790790
69. Le Bon A and Tough DF. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol. (2002) 14:432–6. doi: 10.1016/s0952-7915(02)00354-0, PMID: 12088676
70. Ignarro RS, Bombeiro AL, Chiarotto GB, Cartarozzi LP, Coser LO, Ghizoni E, et al. Interferon-beta induces major histocompatibility complex of class I (Mhc-I) expression and a proinflammatory phenotype in cultivated human astrocytes. Differentiation. (2022) 128:43–56. doi: 10.1016/j.diff.2022.10.004, PMID: 36306693
71. Holzgruber J, Martins C, Kulcsar Z, Duplaine A, Rasbach E, Migayron L, et al. Type I interferon signaling induces melanoma cell-intrinsic pd-1 and its inhibition antagonizes immune checkpoint blockade. Nat Commun. (2024) 15:7165. doi: 10.1038/s41467-024-51496-2, PMID: 39187481
72. Gangaplara A, Martens C, Dahlstrom E, Metidji A, Gokhale AS, Glass DD, et al. Type I interferon signaling attenuates regulatory T cell function in viral infection and in the tumor microenvironment. PloS Pathog. (2018) 14:e1006985. doi: 10.1371/journal.ppat.1006985, PMID: 29672594
73. Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, et al. Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front Immunol. (2018) 9:1310. doi: 10.3389/fimmu.2018.01310, PMID: 29942309
74. Crow MK. Type I interferon in the pathogenesis of lupus. J Immunol. (2014) 192:5459–68. doi: 10.4049/jimmunol.1002795, PMID: 24907379
75. Chiang CY, Veckman V, Limmer K, and David M. Phospholipase Cγ-2 and intracellular calcium are required for lipopolysaccharide-induced toll-like receptor 4 (Tlr4) endocytosis and interferon regulatory factor 3 (IRF3) activation. J Biol Chem. (2012) 287:3704–9. doi: 10.1074/jbc.C111.328559, PMID: 22158869
76. Yoon SI, Kurnasov O, Natarajan V, Hong M, Gudkov AV, Osterman AL, et al. Structural basis of tlr5-flagellin recognition and signaling. Science. (2012) 335:859–64. doi: 10.1126/science.1215584, PMID: 22344444
77. Kawai T and Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. (2010) 11:373–84. doi: 10.1038/ni.1863, PMID: 20404851
78. Erttmann SF, Swacha P, Aung KM, Brindefalk B, Jiang H, Härtlova A, et al. The gut microbiota prime systemic antiviral immunity via the cGAS-STING-IFN-I axis. Immunity. (2022) 55:847–61.e10. doi: 10.1016/j.immuni.2022.04.006, PMID: 35545033
79. Wang G, Liu J, Zhang Y, Xie J, Chen S, Shi Y, et al. Ginsenoside Rg3 enriches SCFA-producing commensal bacteria to confer protection against enteric viral infection via the cGAS-STING-type I IFN axis. Isme J. (2023) 17:2426–40. doi: 10.1038/s41396-023-01541-7, PMID: 37950067
80. Wang J, Huang M, Du Y, Chen H, Li Z, Zhai T, et al. Lactobacillus rhamnosus GG regulates host IFN-I through the RIG-I signalling pathway to inhibit herpes simplex virus type 2 infection. Probiotics Antimicrob Proteins. (2024) 16:1966–78. doi: 10.1007/s12602-023-10137-8, PMID: 37624569
81. Schoenborn JR and Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. (2007) 96:41–101. doi: 10.1016/s0065-2776(07)96002-2, PMID: 17981204
82. Boehm U, Klamp T, Groot M, and Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol. (1997) 15:749–95. doi: 10.1146/annurev.immunol.15.1.749, PMID: 9143706
83. Schroder K, Hertzog PJ, Ravasi T, and Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. (2004) 75:163–89. doi: 10.1189/jlb.0603252, PMID: 14525967
84. Bach EA, Aguet M, and Schreiber RD. The IFN gamma receptor: A paradigm for cytokine receptor signaling. Annu Rev Immunol. (1997) 15:563–91. doi: 10.1146/annurev.immunol.15.1.563, PMID: 9143700
85. Nathan CF, Murray HW, Wiebe ME, and Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. (1983) 158:670–89. doi: 10.1084/jem.158.3.670, PMID: 6411853
86. Ikeda H, Old LJ, and Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. (2002) 13:95–109. doi: 10.1016/s1359-6101(01)00038-7, PMID: 11900986
87. Gocher AM, Workman CJ, and Vignali DAA. Interferon-γ: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. (2022) 22:158–72. doi: 10.1038/s41577-021-00566-3, PMID: 34155388
88. Shvets Y, Khranovska N, Senchylo N, Ostapchenko D, Tymoshenko I, Onysenko S, et al. Microbiota substances modulate dendritic cells activity: A critical view. Heliyon. (2024) 10:e27125. doi: 10.1016/j.heliyon.2024.e27125, PMID: 38444507
89. Cao AT, Yao S, Stefka AT, Liu Z, Qin H, Liu H, et al. TLR4 regulates IFN-γ and IL-17 production by both thymic and induced Foxp3+ Tregs during intestinal inflammation. J Leukoc Biol. (2014) 96:895–905. doi: 10.1189/jlb.3A0114-056RR, PMID: 25015957
90. Valentini M, Piermattei A, Di Sante G, Migliara G, Delogu G, and Ria F. Immunomodulation by gut microbiota: role of toll-like receptor expressed by T cells. J Immunol Res. (2014) 2014:586939. doi: 10.1155/2014/586939, PMID: 25147831
91. Heidari M, Maleki Vareki S, Yaghobi R, and Karimi MH. Microbiota activation and regulation of adaptive immunity. Front Immunol. (2024) 15:1429436. doi: 10.3389/fimmu.2024.1429436, PMID: 39445008
92. Zhou J, Zhuang Z, Li J, and Feng Z. Significance of the cGAS-STING pathway in health and disease. Int J Mol Sci. (2023) 24:13316. doi: 10.3390/ijms241713316, PMID: 37686127
93. Liu N, Pang X, Zhang H, and Ji P. The cGAS-STING pathway in bacterial infection and bacterial immunity. Front Immunol. (2021) 12:814709. doi: 10.3389/fimmu.2021.814709, PMID: 35095914
94. Uribe-Herranz M, Bittinger K, Rafail S, Guedan S, Pierini S, Tanes C, et al. Gut microbiota modulates adoptive cell therapy via CD8α Dendritic cells and IL-12. JCI Insight. (2018) 3:e94952. doi: 10.1172/jci.insight.94952, PMID: 29467322
95. Wilson KR, Gressier E, McConville MJ, and Bedoui S. Microbial metabolites in the maturation and activation of dendritic cells and their relevance for respiratory immunity. Front Immunol. (2022) 13:897462. doi: 10.3389/fimmu.2022.897462, PMID: 35880171
96. Nguyen NT, Nakahama T, Le DH, Van Son L, Chu HH, and Kishimoto T. Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research. Front Immunol. (2014) 5:551. doi: 10.3389/fimmu.2014.00551, PMID: 25400638
97. Gutiérrez-Vázquez C and Quintana FJ. Regulation of the immune response by the aryl hydrocarbon receptor. Immunity. (2018) 48:19–33. doi: 10.1016/j.immuni.2017.12.012, PMID: 29343438
98. Niers LE, Hoekstra MO, Timmerman HM, van Uden NO, de Graaf PM, Smits HH, et al. Selection of probiotic bacteria for prevention of allergic diseases: immunomodulation of neonatal dendritic cells. Clin Exp Immunol. (2007) 149:344–52. doi: 10.1111/j.1365-2249.2007.03421.x, PMID: 17521319
99. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. (2003) 4:63–8. doi: 10.1038/ni873, PMID: 12469119
100. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. (2003) 4:69–77. doi: 10.1038/ni875, PMID: 12483210
101. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene ifnl4 is associated with impaired clearance of hepatitis C virus. Nat Genet. (2013) 45:164–71. doi: 10.1038/ng.2521, PMID: 23291588
102. Odendall C and Kagan JC. The unique regulation and functions of type III interferons in antiviral immunity. Curr Opin Virol. (2015) 12:47–52. doi: 10.1016/j.coviro.2015.02.003, PMID: 25771505
103. Ye L, Schnepf D, and Staeheli P. Interferon-λ Orchestrates innate and adaptive mucosal immune responses. Nat Rev Immunol. (2019) 19:614–25. doi: 10.1038/s41577-019-0182-z, PMID: 31201377
104. Mendoza JL, Schneider WM, Hoffmann HH, Vercauteren K, Jude KM, Xiong A, et al. The IFN-λ-IFN-λR1-IL-10Rβ Complex reveals structural features underlying type III IFN functional plasticity. Immunity. (2017) 46:379–92. doi: 10.1016/j.immuni.2017.02.017, PMID: 28329704
105. Stanifer ML, Kee C, Cortese M, Zumaran CM, Triana S, Mukenhirn M, et al. Critical role of type III interferon in controlling sars-cov-2 infection in human intestinal epithelial cells. Cell Rep. (2020) 32:107863. doi: 10.1016/j.celrep.2020.107863, PMID: 32610043
106. Wells AI and Coyne CB. Type III interferons in antiviral defenses at barrier surfaces. Trends Immunol. (2018) 39:848–58. doi: 10.1016/j.it.2018.08.008, PMID: 30219309
107. Czabotar PE, Lessene G, Strasser A, and Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. (2014) 15:49–63. doi: 10.1038/nrm3722, PMID: 24355989
108. Carneiro BA and El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. (2020) 17:395–417. doi: 10.1038/s41571-020-0341-y, PMID: 32203277
109. Sartorius U, Schmitz I, and Krammer PH. Molecular mechanisms of death-receptor-mediated apoptosis. Chembiochem. (2001) 2:20–9. doi: 10.1002/1439-7633(20010105)2:1<20::Aid-cbic20>3.0.Co;2-x, PMID: 11828422
110. Verbrugge I, Johnstone RW, and Smyth MJ. Snapshot: extrinsic apoptosis pathways. Cell. (2010) 143:1192. e1–2. doi: 10.1016/j.cell.2010.12.004, PMID: 21183080
111. Dadsena S, King LE, and García-Sáez AJ. Apoptosis regulation at the mitochondria membrane level. Biochim Biophys Acta Biomembr. (2021) 1863:183716. doi: 10.1016/j.bbamem.2021.183716, PMID: 34343535
112. Ola MS, Nawaz M, and Ahsan H. Role of BCL-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem. (2011) 351:41–58. doi: 10.1007/s11010-010-0709-x, PMID: 21210296
113. Xuejiao S, Yong X, Ningyu W, Lidan Z, Xuanhong S, Youzhi X, et al. A novel benzothiazole derivative YLT322 induces apoptosis via the mitochondrial apoptosis pathway in vitro with anti-tumor activity in solid Malignancies. PloS One. (2013) 8:e63900. doi: 10.1371/journal.pone.0063900, PMID: 23737957
114. Chen C, Liu Y, Shen Y, Zhu L, Yao L, Wang X, et al. Rosmarinic acid, the active component of rubi fructus, induces apoptosis of SGC-7901 and HepG2 cells through mitochondrial pathway and exerts anti-tumor effect. Naunyn Schmiedebergs Arch Pharmacol. (2023) 396:3743–55. doi: 10.1007/s00210-023-02552-z, PMID: 37338574
115. Kumar S, Eroglu E, Stokes JA 3rd, Scissum-Gunn K, Saldanha SN, Singh UP, et al. Resveratrol induces mitochondria-mediated, caspase-independent apoptosis in murine prostate cancer cells. Oncotarget. (2017) 8:20895–908. doi: 10.18632/oncotarget.14947, PMID: 28157696
116. Li T, Xu XH, Tang ZH, Wang YF, Leung CH, Ma DL, et al. Platycodin D induces apoptosis and triggers ERK- and JNK-mediated autophagy in human hepatocellular carcinoma BEL-7402 cells. Acta Pharmacol Sin. (2015) 36:1503–13. doi: 10.1038/aps.2015.99, PMID: 26592509
117. Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, et al. Mechanisms of interferon-alpha induced apoptosis in Malignant cells. Oncogene. (2002) 21:1251–62. doi: 10.1038/sj.onc.1205179, PMID: 11850845
118. Shi W, Yao X, Fu Y, and Wang Y. Interferon-α and its effects on cancer cell apoptosis. Oncol Lett. (2022) 24:235. doi: 10.3892/ol.2022.13355, PMID: 35720476
119. Jena KK, Mambu J, Boehmer D, Sposito B, Millet V, de Sousa Casal J, et al. Type III interferons induce pyroptosis in gut epithelial cells and impair mucosal repair. Cell. (2024) 187:7533–50.e23. doi: 10.1016/j.cell.2024.10.010, PMID: 39500322
120. Simpson DS, Pang J, Weir A, Kong IY, Fritsch M, Rashidi M, et al. Interferon-γ primes macrophages for pathogen ligand-induced killing via a caspase-8 and mitochondrial cell death pathway. Immunity. (2022) 55:423–41.e9. doi: 10.1016/j.immuni.2022.01.003, PMID: 35139355
121. Rongvaux A, Jackson R, Harman Christian CD, Li T, West AP, de Zoete Marcel R, et al. Apoptotic caspases prevent the induction of type I interferons by mitochondrial DNA. Cell. (2014) 159:1563–77. doi: 10.1016/j.cell.2014.11.037, PMID: 25525875
122. Cristina Carrillo M, de Luján Álvarez M, and Darío Quiroga A. Interferon alfa-2b triggers transforming growth factor-β1-induced apoptosis on preneoplastic liver. Ann Hepatol. (2006) 5:244–50. doi: 10.1016/S1665-2681(19)31982-9, PMID: 17153763
123. Mizushima N, Levine B, Cuervo AM, and Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. (2008) 451:1069–75. doi: 10.1038/nature06639, PMID: 18305538
124. Mizushima N and Komatsu M. Autophagy: renovation of cells and tissues. Cell. (2011) 147:728–41. doi: 10.1016/j.cell.2011.10.026, PMID: 22078875
125. Levine B and Kroemer G. Biological functions of autophagy genes: A disease perspective. Cell. (2019) 176:11–42. doi: 10.1016/j.cell.2018.09.048, PMID: 30633901
126. Kaushik S and Cuervo AM. The coming of age of chaperone-mediated autophagy. Nat Rev Mol Cell Biol. (2018) 19:365–81. doi: 10.1038/s41580-018-0001-6, PMID: 29626215
127. Li P, Du Q, Cao Z, Guo Z, Evankovich J, Yan W, et al. Interferon-γ Induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1). Cancer Lett. (2012) 314:213–22. doi: 10.1016/j.canlet.2011.09.031, PMID: 22056812
128. Wang QS, Shen SQ, Sun HW, Xing ZX, and Yang HL. Interferon-gamma induces autophagy-associated apoptosis through induction of cPLA2-dependent mitochondrial ROS generation in colorectal cancer cells. Biochem Biophys Res Commun. (2018) 498:1058–65. doi: 10.1016/j.bbrc.2018.03.118, PMID: 29551681
129. Zhao J, Wang ML, Li Z, Gao DM, Cai Y, Chang J, et al. Interferon-alpha-2b induces autophagy in hepatocellular carcinoma cells through beclin1 pathway. Cancer Biol Med. (2014) 11:64–8. doi: 10.7497/j.issn.2095-3941.2014.01.006, PMID: 24738040
130. Nehammer C, Ejlerskov P, Gopal S, Handley A, Ng L, Moreira P, et al. Interferon-β-induced miR-1 alleviates toxic protein accumulation by controlling autophagy. Elife. (2019) 8:e49930. doi: 10.7554/eLife.49930, PMID: 31799933
131. Gao D, Zhao J, Li X, Xia Y, Cai Y, Pan J, et al. Interferon-λ1 suppresses invasion and enhances autophagy in human osteosarcoma cell. Int J Clin Exp Med. (2015) 8:14999–5004., PMID: 26628983
132. Gui X, Yang H, Li T, Tan X, Shi P, Li M, et al. Autophagy induction via sting trafficking is a primordial function of the cGAS pathway. Nature. (2019) 567:262–6. doi: 10.1038/s41586-019-1006-9, PMID: 30842662
133. Rathinam VA and Fitzgerald KA. Inflammasome complexes: emerging mechanisms and effector functions. Cell. (2016) 165:792–800. doi: 10.1016/j.cell.2016.03.046, PMID: 27153493
134. Shi J, Gao W, and Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci. (2017) 42:245–54. doi: 10.1016/j.tibs.2016.10.004, PMID: 27932073
135. Broz P and Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. (2016) 16:407–20. doi: 10.1038/nri.2016.58, PMID: 27291964
136. Kayagaki N, Stowe IB, Lee BL, O'Rourke K, Anderson K, Warming S, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature. (2015) 526:666–71. doi: 10.1038/nature15541, PMID: 26375259
137. Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. (2015) 526:660–5. doi: 10.1038/nature15514, PMID: 26375003
138. Li Y, Guo X, Hu C, Du Y, Guo C, Di W, et al. Type I ifn operates pyroptosis and necroptosis during multidrug-resistant A. Baumannii Infection. Cell Death Differ. (2018) 25:1304–18. doi: 10.1038/s41418-017-0041-z, PMID: 29352265
139. Peng Y, Yang Y, Li Y, Shi T, Xu N, Liu R, et al. Mitochondrial (Mt)DNA-cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (Sting) signaling promotes pyroptosis of macrophages via interferon regulatory factor (IRF)7/IRF3 activation to aggravate lung injury during severe acute pancreatitis. Cell Mol Biol Lett. (2024) 29:61. doi: 10.1186/s11658-024-00575-9, PMID: 38671352
140. Chiba Y, Doi T, Obayashi K, Sumida K, Nagasaka S, Wang K-Y, et al. Caspase-4 promotes metastasis and interferon-γ-induced pyroptosis in lung adenocarcinoma. Commun Biol. (2024) 7:699. doi: 10.1038/s42003-024-06402-3, PMID: 38849594
141. Arimoto KI, Miyauchi S, Troutman TD, Zhang Y, Liu M, Stoner SA, et al. Expansion of interferon inducible gene pool via USP18 inhibition promotes cancer cell pyroptosis. Nat Commun. (2023) 14:251. doi: 10.1038/s41467-022-35348-5, PMID: 36646704
142. Wu S, Wang B, Li H, Wang H, Du S, Huang X, et al. Targeting STING elicits GSDMD-dependent pyroptosis and boosts anti-tumor immunity in renal cell carcinoma. Oncogene. (2024) 43:1534–48. doi: 10.1038/s41388-024-03013-4, PMID: 38548966
143. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. (2012) 149:1060–72. doi: 10.1016/j.cell.2012.03.042, PMID: 22632970
144. Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell. (2017) 171:273–85. doi: 10.1016/j.cell.2017.09.021, PMID: 28985560
145. Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. (2014) 156:317–31. doi: 10.1016/j.cell.2013.12.010, PMID: 24439385
146. Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, et al. Acsl4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. (2017) 13:91–8. doi: 10.1038/nchembio.2239, PMID: 27842070
147. Doll S and Conrad M. Iron and ferroptosis: A still ill-defined liaison. IUBMB Life. (2017) 69:423–34. doi: 10.1002/iub.1616, PMID: 28276141
148. Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a P53-mediated activity during tumour suppression. Nature. (2015) 520:57–62. doi: 10.1038/nature14344, PMID: 25799988
149. Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. (2019) 575:688–92. doi: 10.1038/s41586-019-1705-2, PMID: 31634900
150. Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al. Fsp1 is a glutathione-independent ferroptosis suppressor. Nature. (2019) 575:693–8. doi: 10.1038/s41586-019-1707-0, PMID: 31634899
151. Jiang X, Stockwell BR, and Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. (2021) 22:266–82. doi: 10.1038/s41580-020-00324-8, PMID: 33495651
152. Chen X, Kang R, Kroemer G, and Tang D. Ferroptosis in infection, inflammation, and immunity. J Exp Med. (2021) 218:e20210518. doi: 10.1084/jem.20210518, PMID: 33978684
153. Cao T, Zhou J, Liu Q, Mao T, Chen B, Wu Q, et al. Interferon-γ Induces salivary gland epithelial cell ferroptosis in sjogren's syndrome via JAK/STAT1-mediated inhibition of system xc(). Free Radic Biol Med. (2023) 205:116–28. doi: 10.1016/j.freeradbiomed.2023.05.027, PMID: 37286044
154. Tao Q, Liu N, Wu J, Chen J, Chen X, and Peng C. Mefloquine enhances the efficacy of anti-PD-1 immunotherapy via IFN-γ-STAT1-IRF1-LPCAT3-induced ferroptosis in tumors. J Immunother Cancer. (2024) 12:e008554. doi: 10.1136/jitc-2023-008554, PMID: 38471712
155. Zhu J, Li X, Chen W, Zuo Z, Gong Q, Hu J, et al. Ferroptosis triggers anti-tumor immunity via promoting chaperone-mediated autophagic degradation of SHP2. Redox Biol. (2025) 86:103796. doi: 10.1016/j.redox.2025.103796, PMID: 40759058
156. Li M, Jin S, Ma H, Yang X, and Zhang Z. Reciprocal regulation between ferroptosis and sting-type I interferon pathway suppresses head and neck squamous cell carcinoma growth through dendritic cell maturation. Oncogene. (2025) 44:1922–35. doi: 10.1038/s41388-025-03368-2, PMID: 40164871
157. Bao Y, Pan Z, Zhao L, Qiu J, Cheng J, Liu L, et al. BIBR1532 combined with radiotherapy induces ferroptosis in NSCLC cells and activates cGAS-STING pathway to promote anti-tumor immunity. J Transl Med. (2024) 22:519. doi: 10.1186/s12967-024-05331-3, PMID: 38816831
158. Liao P, Wang W, Wang W, Kryczek I, Li X, Bian Y, et al. CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell. (2022) 40:365–78.e6. doi: 10.1016/j.ccell.2022.02.003, PMID: 35216678
159. Ganal SC, Sanos SL, Kallfass C, Oberle K, Johner C, Kirschning C, et al. Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota. Immunity. (2012) 37:171–86. doi: 10.1016/j.immuni.2012.05.020, PMID: 22749822
160. Lee W, Kim M, Lee SH, Jung HG, and Oh JW. Prophylactic efficacy of orally administered bacillus poly-γ-glutamic acid, a non-LPS TLR4 ligand, against norovirus infection in mice. Sci Rep. (2018) 8:8667. doi: 10.1038/s41598-018-26935-y, PMID: 29875467
161. Stefan KL, Kim MV, Iwasaki A, and Kasper DL. Commensal microbiota modulation of natural resistance to virus infection. Cell. (2020) 183:1312–24.e10. doi: 10.1016/j.cell.2020.10.047, PMID: 33212011
162. Gutierrez-Merino J, Isla B, Combes T, Martinez-Estrada F, and Maluquer De Motes C. Beneficial bacteria activate type-I interferon production via the intracellular cytosolic sensors STING and MAVS. Gut Microbes. (2020) 11:771–88. doi: 10.1080/19490976.2019.1707015, PMID: 31941397
163. Kawashima T, Kosaka A, Yan H, Guo Z, Uchiyama R, Fukui R, et al. Double-stranded RNA of intestinal commensal but not pathogenic bacteria triggers production of protective interferon-β. Immunity. (2013) 38:1187–97. doi: 10.1016/j.immuni.2013.02.024, PMID: 23791646
164. Antunes KH, Fachi JL, de Paula R, da Silva EF, Pral LP, Dos Santos A, et al. Microbiota-Derived Acetate Protects against Respiratory Syncytial Virus Infection through a Gpr43-Type 1 Interferon Response. Nat Commun. (2019) 10:3273. doi: 10.1038/s41467-019-11152-6, PMID: 31332169
165. Winkler ES, Shrihari S, Hykes BL Jr., Handley SA, Andhey PS, Huang YS, et al. The intestinal microbiome restricts alphavirus infection and dissemination through a bile acid-type I IFN signaling axis. Cell. (2020) 182:901–18.e18. doi: 10.1016/j.cell.2020.06.029, PMID: 32668198
166. Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, et al. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene. (2003) 22:1653–62. doi: 10.1038/sj.onc.1206139, PMID: 12642868
167. Li T, Dong ZR, Guo ZY, Wang CH, Tang ZY, Qu SF, et al. Aspirin enhances IFN-α-induced growth inhibition and apoptosis of hepatocellular carcinoma via jak1/stat1 pathway. Cancer Gene Ther. (2013) 20:366–74. doi: 10.1038/cgt.2013.29, PMID: 23703473
168. Shi WY, Cao C, and Liu L. Interferon α Induces the apoptosis of cervical cancer HeLa cells by activating both the intrinsic mitochondrial pathway and endoplasmic reticulum stress-induced pathway. Int J Mol Sci. (2016) 17:1832. doi: 10.3390/ijms17111832, PMID: 27827850
169. Marcus A, Mao AJ, Lensink-Vasan M, Wang L, Vance RE, and Raulet DH. Tumor-derived cGAMP triggers a sting-mediated interferon response in non-tumor cells to activate the NK cell response. Immunity. (2018) 49:754–63.e4. doi: 10.1016/j.immuni.2018.09.016, PMID: 30332631
170. Leventhal DS, Sokolovska A, Li N, Plescia C, Kolodziej SA, Gallant CW, et al. Immunotherapy with engineered bacteria by targeting the sting pathway for anti-tumor immunity. Nat Commun. (2020) 11:2739. doi: 10.1038/s41467-020-16602-0, PMID: 32483165
171. Parker BS, Rautela J, and Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. (2016) 16:131–44. doi: 10.1038/nrc.2016.14, PMID: 26911188
172. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, and Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces bax and promotes cell death. Cell. (1995) 80:285–91. doi: 10.1016/0092-8674(95)90411-5, PMID: 7834748
173. Zitzmann K, Brand S, De Toni EN, Baehs S, Göke B, Meinecke J, et al. SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res. (2007) 67:5025–32. doi: 10.1158/0008-5472.Can-06-2575, PMID: 17510435
174. Medrano RFV, Hunger A, Mendonça SA, Barbuto JAM, and Strauss BE. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget. (2017) 8:71249–84. doi: 10.18632/oncotarget.19531, PMID: 29050360
175. Dong H, Zhu L, Sun J, Chen Q, Liu P, Zhang W, et al. IFNβ Drives ferroptosis through elevating TRIM22 and promotes the cytotoxicity of RSL3. Front Immunol. (2025) 16:1535554. doi: 10.3389/fimmu.2025.1535554, PMID: 39975542
176. Zhang S, Kang L, Dai X, Chen J, Chen Z, Wang M, et al. Manganese induces tumor cell ferroptosis through type-I IFN dependent inhibition of mitochondrial dihydroorotate dehydrogenase. Free Radic Biol Med. (2022) 193:202–12. doi: 10.1016/j.freeradbiomed.2022.10.004, PMID: 36228830
177. Pilla DM, Hagar JA, Haldar AK, Mason AK, Degrandi D, Pfeffer K, et al. Guanylate binding proteins promote caspase-11-dependent pyroptosis in response to cytoplasmic LPS. Proc Natl Acad Sci U.S.A. (2014) 111:6046–51. doi: 10.1073/pnas.1321700111, PMID: 24715728
178. Du W, Frankel TL, Green M, and Zou W. IFNγ Signaling integrity in colorectal cancer immunity and immunotherapy. Cell Mol Immunol. (2022) 19:23–32. doi: 10.1038/s41423-021-00735-3, PMID: 34385592
179. Castleman MJ, Dillon SM, Purba C, Cogswell AC, McCarter M, Barker E, et al. Enteric bacteria induce IFNγ and granzyme B from human colonic group 1 innate lymphoid cells. Gut Microbes. (2020) 12:1667723. doi: 10.1080/19490976.2019.1667723, PMID: 31583949
180. Luu M, Weigand K, Wedi F, Breidenbend C, Leister H, Pautz S, et al. Regulation of the effector function of CD8(+) T cells by gut microbiota-derived metabolite butyrate. Sci Rep. (2018) 8:14430. doi: 10.1038/s41598-018-32860-x, PMID: 30258117
181. Lun H, Li P, Li J, and Liu F. The effect of intestinal flora metabolites on macrophage polarization. Heliyon. (2024) 10:e35755. doi: 10.1016/j.heliyon.2024.e35755, PMID: 39170251
182. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science. (2018) 359:91–7. doi: 10.1126/science.aan3706, PMID: 29097494
183. de Oliveira Alves N, Dalmasso G, Nikitina D, Vaysse A, Ruez R, Ledoux L, et al. The colibactin-producing escherichia coli alters the tumor microenvironment to immunosuppressive lipid overload facilitating colorectal cancer progression and chemoresistance. Gut Microbes. (2024) 16:2320291. doi: 10.1080/19490976.2024.2320291, PMID: 38417029
184. Wang L, Wang Y, Song Z, Chu J, and Qu X. Deficiency of interferon-gamma or its receptor promotes colorectal cancer development. J Interferon Cytokine Res. (2015) 35:273–80. doi: 10.1089/jir.2014.0132, PMID: 25383957
185. Tanoue T, Morita S, Plichta DR, Skelly AN, Suda W, Sugiura Y, et al. A defined commensal consortium elicits cd8 T cells and anti-cancer immunity. Nature. (2019) 565:600–5. doi: 10.1038/s41586-019-0878-z, PMID: 30675064
186. Bender MJ, McPherson AC, Phelps CM, Pandey SP, Laughlin CR, Shapira JH, et al. Dietary tryptophan metabolite released by intratumoral lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell. (2023) 186:1846–62.e26. doi: 10.1016/j.cell.2023.03.011, PMID: 37028428
187. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis. (2003) 8:237–49. doi: 10.1023/a:1023668705040, PMID: 12766484
188. Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. (2011) 71:768–78. doi: 10.1158/0008-5472.Can-10-2788, PMID: 21156650
189. Thapa RJ, Basagoudanavar SH, Nogusa S, Irrinki K, Mallilankaraman K, Slifker MJ, et al. Nf-kappaB protects cells from gamma interferon-induced RIP1-dependent necroptosis. Mol Cell Biol. (2011) 31:2934–46. doi: 10.1128/mcb.05445-11, PMID: 21576359
190. Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. (2019) 569:270–4. doi: 10.1038/s41586-019-1170-y, PMID: 31043744
191. Yang YB, Zhou JX, Qiu SH, He JS, Pan JH, and Pan YL. Identification of a novel ferroptosis-related gene prediction model for clinical prognosis and immunotherapy of colorectal cancer. Dis Markers. (2021) 2021:4846683. doi: 10.1155/2021/4846683, PMID: 34868393
192. Du S, Zeng F, Sun H, Liu Y, Han P, Zhang B, et al. Prognostic and therapeutic significance of a novel ferroptosis related signature in colorectal cancer patients. Bioengineered. (2022) 13:2498–512. doi: 10.1080/21655979.2021.2017627, PMID: 35067161
193. Xia W, Lv Y, Zou Y, Kang Z, Li Z, Tian J, et al. The role of ferroptosis in colorectal cancer and its potential synergy with immunotherapy. Front Immunol. (2024) 15:1526749. doi: 10.3389/fimmu.2024.1526749, PMID: 39850905
194. Sommereyns C, Paul S, Staeheli P, and Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PloS Pathog. (2008) 4:e1000017. doi: 10.1371/journal.ppat.1000017, PMID: 18369468
195. Baldridge MT, Nice TJ, McCune BT, Yokoyama CC, Kambal A, Wheadon M, et al. Commensal microbes and interferon-λ Determine persistence of enteric murine norovirus infection. Science. (2015) 347:266–9. doi: 10.1126/science.1258025, PMID: 25431490
196. Grau KR, Zhu S, Peterson ST, Helm EW, Philip D, Phillips M, et al. The intestinal regionalization of acute norovirus infection is regulated by the microbiota via bile acid-mediated priming of type III interferon. Nat Microbiol. (2020) 5:84–92. doi: 10.1038/s41564-019-0602-7, PMID: 31768030
197. Van Winkle JA, Peterson ST, Kennedy EA, Wheadon MJ, Ingle H, Desai C, et al. Homeostatic interferon-lambda response to bacterial microbiota stimulates preemptive antiviral defense within discrete pockets of intestinal epithelium. Elife. (2022) 11:e74072. doi: 10.7554/eLife.74072, PMID: 35137688
198. Li W, Lewis-Antes A, Huang J, Balan M, and Kotenko SV. Regulation of apoptosis by type III interferons. Cell Prolif. (2008) 41:960–79. doi: 10.1111/j.1365-2184.2008.00558.x, PMID: 19040572
199. Hui X, Chen H, Zhang S, Ma X, Wang X, and Huang B. Antitumor activities of recombinant human interferon (IFN)-λ1 in vitro and in xenograft models in vivo for colon cancer. Cancer Lett. (2011) 311:141–51. doi: 10.1016/j.canlet.2011.07.004, PMID: 21872388
200. Broggi A, Granucci F, and Zanoni I. Type III interferons: balancing tissue tolerance and resistance to pathogen invasion. J Exp Med. (2020) 217:e20190295. doi: 10.1084/jem.20190295, PMID: 31821443
201. Tang R, Xu J, Zhang B, Liu J, Liang C, Hua J, et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. (2020) 13:110. doi: 10.1186/s13045-020-00946-7, PMID: 32778143
202. Wang J, Lu W, Zhang J, Du Y, Fang M, Zhang A, et al. Loss of TRIM29 mitigates viral myocarditis by attenuating perk-driven ER stress response in male mice. Nat Commun. (2024) 15:3481. doi: 10.1038/s41467-024-44745-x, PMID: 38664417
203. Wang J, Wang L, Lu W, Farhataziz N, Gonzalez A, Xing J, et al. TRIM29 controls enteric RNA virus-induced intestinal inflammation by targeting NLRP6 and NLRP9b signaling pathways. Mucosal Immunol. (2025) 18:135–50. doi: 10.1016/j.mucimm.2024.10.004, PMID: 39396665
204. Chen Y, Ma J, and Zhang M. TRIM29 promotes the progression of colorectal cancer by suppressing EZH2 degradation. Exp Biol Med (Maywood). (2023) 248:1527–36. doi: 10.1177/15353702231199070, PMID: 37837384
205. Sun J, Zhang T, Cheng M, Hong L, Zhang C, Xie M, et al. TRIM29 facilitates the epithelial-to-mesenchymal transition and the progression of colorectal cancer via the activation of the Wnt/β-catenin signaling pathway. J Exp Clin Cancer Res. (2019) 38:104. doi: 10.1186/s13046-019-1098-y, PMID: 30813948
206. Lei W, Zhou K, Lei Y, Li Q, and Zhu H. Gut microbiota shapes cancer immunotherapy responses. NPJ Biofilms Microbiomes. (2025) 11:143. doi: 10.1038/s41522-025-00786-8, PMID: 40715107
207. Acha-Sagredo A, Andrei P, Clayton K, Taggart E, Antoniotti C, Woodman CA, et al. A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer. Cancer Cell. (2025) 43:292–307.e7. doi: 10.1016/j.ccell.2024.12.008, PMID: 39824178
208. Kim Y, Kim G, Kim S, Cho B, Kim S-Y, Do E-J, et al. Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor. Cell Host Microbe. (2024) 32:1380–93.e9. doi: 10.1016/j.chom.2024.06.010, PMID: 39059396
209. Lynch LE, Lahowetz R, Maresso C, Terwilliger A, Pizzini J, Melendez Hebib V, et al. Present and future of microbiome-targeting therapeutics. J Clin Invest. (2025) 135:e184323. doi: 10.1172/jci184323, PMID: 40454480
210. Kang X, Lau HC-H, and Yu J. Modulating gut microbiome in cancer immunotherapy: harnessing microbes to enhance treatment efficacy. Cell Rep Med. (2024) 5:101478. doi: 10.1016/j.xcrm.2024.101478, PMID: 38631285
Keywords: colorectal cancer, gut microbiota, immune microenvironment, interferon, programmed cell death
Citation: Yao Q, Chen S, Qian W, Yang C and Li J (2026) Role and mechanism of gut microbiota in regulating interferon-mediated programmed cell death in colorectal cancer. Front. Immunol. 16:1724908. doi: 10.3389/fimmu.2025.1724908
Received: 14 October 2025; Accepted: 22 December 2025; Revised: 21 December 2025;
Published: 12 January 2026.
Edited by:
Junji Xing, Houston Methodist Research Institute, United StatesReviewed by:
Omkar Shinde, Sinhgad Dental College and Hospital, IndiaJinlong Wan, LMU Munich University Hospital, Germany
Copyright © 2026 Yao, Chen, Qian, Yang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Junxian Li, d2V3b3Jrb2h5ZUAxNjMuY29t; Chao Yang, MTgzMjgzMzUzMjZAMTYzLmNvbQ==
†These authors have contributed equally to this work and share first authorship